Skip to content

Study · Non-randomized trial · n = 428 · 2009

7 results

Active comparator trial of teriparatide vs alendronate for treating glucocorticoid-induced osteoporosis: results from the Hispanic and non-Hispanic cohorts.

Losada BR, Zanchetta JR, Zerbini C, Molina JF, De la Peña P, Liu CC, Smith RB, Nino AJ, Krohn K, Warner MR

Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry22 Nov 2008Cited by 13 (Europe PMC)

PMID19028124 (opens in a new tab)DOI10.1016/j.jocd.2008.10.002 (opens in a new tab)PepBankPUB-19028124
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialSafety outcome

    In patients with glucocorticoid-induced osteoporosis, the number reporting at least one adverse event did not differ significantly between teriparatide and alendronate in either the Hispanic or the non-Hispanic cohort.

    In plain wordsIn patients with glucocorticoid-induced osteoporosis, the number reporting at least one adverse event did not differ significantly between teriparatide and alendronate in either cohort.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeAt least one adverse event, both cohorts
    Study

    n = 428

    Comparator
    Alendronate
    Outcome group
    Adverse events · Whole body
    Studied dose
    20 microg/d · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    The number of patients reporting >or=1 adverse event was not significantly different between treatments in either cohort, with more patients reporting nausea in the teriparatide group.
    2 context sentences
    Summary · context
    This post hoc analysis compared teriparatide vs alendronate on bone mineral density (BMD) in Hispanic and non-Hispanic patients with glucocorticoid-induced osteoporosis.
    Summary · context
    The present study analyzed results from the Hispanic (n=61) and non-Hispanic (n=367) cohorts.
  2. 02HumanNon-randomized trialSafety outcome

    In patients with glucocorticoid-induced osteoporosis, more patients reported nausea with teriparatide than alendronate.

    In plain wordsIn patients with glucocorticoid-induced osteoporosis, more patients reported nausea with teriparatide than alendronate.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseNausea
    Study

    n = 428

    Comparator
    Alendronate
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    20 microg/d · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    The number of patients reporting >or=1 adverse event was not significantly different between treatments in either cohort, with more patients reporting nausea in the teriparatide group.
    2 context sentences
    Summary · context
    This post hoc analysis compared teriparatide vs alendronate on bone mineral density (BMD) in Hispanic and non-Hispanic patients with glucocorticoid-induced osteoporosis.
    Summary · context
    The present study analyzed results from the Hispanic (n=61) and non-Hispanic (n=367) cohorts.
  3. 03HumanNon-randomized trialSafety outcome

    In non-Hispanic patients with glucocorticoid-induced osteoporosis, reports of at least one adverse event did not differ significantly between teriparatide and alendronate.

    In plain wordsIn non-Hispanic patients, reports of at least one adverse event did not differ significantly between teriparatide and alendronate.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeAt least one adverse event, non-Hispanic cohort
    Study

    n = 367

    Comparator
    Alendronate
    Outcome group
    Adverse events · Whole body
    Studied dose
    20 microg/d · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    The number of patients reporting >or=1 adverse event was not significantly different between treatments in either cohort, with more patients reporting nausea in the teriparatide group.
    2 context sentences
    Summary · context
    This post hoc analysis compared teriparatide vs alendronate on bone mineral density (BMD) in Hispanic and non-Hispanic patients with glucocorticoid-induced osteoporosis.
    Summary · context
    The present study analyzed results from the Hispanic (n=61) and non-Hispanic (n=367) cohorts.
  4. 04HumanNon-randomized trialEfficacy outcome

    In Hispanic patients with glucocorticoid-induced osteoporosis, teriparatide increased lumbar spine BMD more than alendronate, 9.8% versus 4.2%.

    In plain wordsIn Hispanic patients with glucocorticoid-induced osteoporosis, teriparatide increased lower spine bone density more than alendronate.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseLumbar spine BMD, Hispanic cohort
    Study

    n = 61

    Comparator
    Alendronate
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 microg/d · 18 monthsAs given in this study (human).

    Measurements

    Lumbar spine BMD change from baseline at 18 months
    9.8%
    Teriparatide group, Hispanic cohort (SE 1.7)
    Lumbar spine BMD change from baseline at 18 months
    4.2%
    Alendronate group, Hispanic cohort (SE 1.4)

    Source sentences

    Summary
    In the Hispanic cohort at 18 mo, there were significantly greater increases from baseline in the teriparatide vs alendronate group in lumbar spine BMD (9.8%+/-1.7% vs 4.2%+/-1.4%; p<0.001; mean+/-SE) and total hip BMD (5.9%+/-1.6% vs 1.3%+/-1.3%, p<0.001), with no significant difference between grou…
    2 context sentences
    Summary · context
    This post hoc analysis compared teriparatide vs alendronate on bone mineral density (BMD) in Hispanic and non-Hispanic patients with glucocorticoid-induced osteoporosis.
    Summary · context
    The present study analyzed results from the Hispanic (n=61) and non-Hispanic (n=367) cohorts.
  5. 05HumanNon-randomized trialEfficacy outcome

    In Hispanic patients with glucocorticoid-induced osteoporosis, teriparatide increased total hip BMD more than alendronate, 5.9% versus 1.3%.

    In plain wordsIn Hispanic patients with glucocorticoid-induced osteoporosis, teriparatide increased total hip bone density more than alendronate.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTotal hip BMD, Hispanic cohort
    Study

    n = 61

    Comparator
    Alendronate
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 microg/d · 18 monthsAs given in this study (human).

    Measurements

    Total hip BMD change from baseline at 18 months
    5.9%
    Teriparatide group, Hispanic cohort (SE 1.6)
    Total hip BMD change from baseline at 18 months
    1.3%
    Alendronate group, Hispanic cohort (SE 1.3)

    Source sentences

    Summary
    In the Hispanic cohort at 18 mo, there were significantly greater increases from baseline in the teriparatide vs alendronate group in lumbar spine BMD (9.8%+/-1.7% vs 4.2%+/-1.4%; p<0.001; mean+/-SE) and total hip BMD (5.9%+/-1.6% vs 1.3%+/-1.3%, p<0.001), with no significant difference between grou…
    2 context sentences
    Summary · context
    This post hoc analysis compared teriparatide vs alendronate on bone mineral density (BMD) in Hispanic and non-Hispanic patients with glucocorticoid-induced osteoporosis.
    Summary · context
    The present study analyzed results from the Hispanic (n=61) and non-Hispanic (n=367) cohorts.
  6. 06HumanNon-randomized trialEfficacy outcome

    In Hispanic patients with glucocorticoid-induced osteoporosis, femoral neck BMD changes did not differ significantly between teriparatide and alendronate.

    In plain wordsIn Hispanic patients with glucocorticoid-induced osteoporosis, femoral neck bone density changes did not differ significantly between teriparatide and alendronate.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeFemoral neck BMD, Hispanic cohort
    Study

    n = 61

    Comparator
    Alendronate
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 microg/d · 18 monthsAs given in this study (human).

    Measurements

    Femoral neck BMD change from baseline at 18 months
    4.3%
    Teriparatide group, Hispanic cohort (SE 2.2)
    Femoral neck BMD change from baseline at 18 months
    2%
    Alendronate group, Hispanic cohort (SE 1.8)

    Source sentences

    Summary
    In the Hispanic cohort at 18 mo, there were significantly greater increases from baseline in the teriparatide vs alendronate group in lumbar spine BMD (9.8%+/-1.7% vs 4.2%+/-1.4%; p<0.001; mean+/-SE) and total hip BMD (5.9%+/-1.6% vs 1.3%+/-1.3%, p<0.001), with no significant difference between grou…
    2 context sentences
    Summary · context
    This post hoc analysis compared teriparatide vs alendronate on bone mineral density (BMD) in Hispanic and non-Hispanic patients with glucocorticoid-induced osteoporosis.
    Summary · context
    The present study analyzed results from the Hispanic (n=61) and non-Hispanic (n=367) cohorts.

Studies that did not test the peptide alone1

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 07HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome

    In patients with glucocorticoid-induced osteoporosis, BMD responses did not differ significantly between the Hispanic and non-Hispanic cohorts within each treatment group (teriparatide and alendronate).

    In plain wordsIn patients with glucocorticoid-induced osteoporosis, bone density responses did not differ significantly between Hispanic and non-Hispanic cohorts within each treatment group.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeBMD response by ethnicity
    Study

    n = 428

    Comparator
    Hispanic versus non-Hispanic cohort within each treatment group (teriparatide and alendronate)
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Within each treatment group, the BMD responses were not significantly different in the Hispanic vs non-Hispanic cohort.
    2 context sentences
    Summary · context
    This post hoc analysis compared teriparatide vs alendronate on bone mineral density (BMD) in Hispanic and non-Hispanic patients with glucocorticoid-induced osteoporosis.
    Summary · context
    The present study analyzed results from the Hispanic (n=61) and non-Hispanic (n=367) cohorts.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.